Product Details
Ferriprox
Deferiprone1000 mg
Tablet
DIN/PIN/NPN
02436558
Manufacturer
Chiesi Canada Corp.
Formulary Listing Date
2021-04-22
Unit Price
33.4740
Amount MOH Pays
33.4740
Coverage Status
Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
V03AC02
Interchangeable Products
NOLU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Blood Modifiers | Deferiprone
For the treatment of patients with transfusional iron overload due to thalassemia syndromes who cannot be adequately treated with deferoxamine or deferasirox. Notes:
Duration of Approval: 5 years Renewals will be considered for Patients who continue to require iron chelation therapy and has had a consistent response to therapy (demonstrated by a reduction in baseline liver iron concentration (LIC) levels). The following documentation is required:
|